City of Hope
Natera Minimal Residual Disease Test Value Called Into Question by City of Hope CRC Patient Data
Based on the results of their new study, City of Hope researchers advised doctors against overreliance on Natera's Signatera assays for recurrence monitoring.
Aiming to Cut Unnecessary Surgeries, City of Hope Team to Commercialize CRC Metastasis Dx Signature
The team will use the reverse-transcriptase quantitative PCR test, which uses a milliliter of a patient's blood, to curb unneeded radical colon cancer surgeries.
Precision Medicine Platform for Oncology Aims to Streamline Molecular Testing, Therapy Decision-Making
City of Hope and Texas Oncology are the first customers for Trapelo, a decision support platform from Innovation Insights that involves labs and payors.
DxTerity, City of Hope Partner to Develop Blood Test for Radiation Therapy Response
DxTerity aims to develop a genomic blood test to identify which cancer patients are most likely to benefit from radiation therapy or are at risk for toxicity.